奥密克戎变异毒株的出现让全球新冠确诊人数再次激增。2020年，新冠病毒快速在全球范围扩散。随后，虽然出现阿尔法等变异毒株，但新增确诊病例的数量并未出现大幅激增。2021年11月，南非首次发现出的奥密克戎变异株，其传播能力远超之前的毒株类型。2022年初全球每日新冠确诊人数激增，在2022年1月末达到波峰，最高时单日新增达到426万，奥密克戎也在2022年迅速成为最主要的流行毒株。

mRNA 被称为“万 能钥匙”，理论上能够表达任何蛋白质，可以探索治疗几乎所有基于蛋白质的疾 病。mRNA 技术的应用领域主要分为免疫疗法、蛋白质替代疗法和再生医学疗 法，在新冠疫苗研发中，mRNA 技术首次得到产业化验证，重点体现出其蛋白 表达能力强，研发周期短的独特优势，目前mRNA 技术已逐步推进至蛋白替代 疗法，细胞治疗等领域，其未来产业化应用场景十分丰富。根据BMC 相关统 计，2025 年全球抗体药物市场可达3000 亿美金， mRNA 技术作为可与抗体 媲美的治疗手段，考虑到治疗方式的突破性、新冠疫情的助力以及技术更迭加 速等情况，我们预计未来mRNA 疫苗和药物市场规模也将达到万亿以上。

全国疫情多地反复，上海日新增感染者人数处于高位。今年3 月以 来，我国新冠疫情波及30 个省（区、市），大部分省市疫情总体可控， 吉林省疫情整体呈下降趋势，上海市新增阳性病例仍处于高位，但相 对维持稳定。

The AI in healthcare was introduced back in the 1960s with simple CAD systems for chest X-Ray and mammography applications. In recent years, AI-based systems have shown a stronghold on major technological advancement in the healthcare ecosystem, evolving around patient-centric and value-based care models. According to one of the key vendors of medical imaging Koninklijke Philips N.V., nearly 60% of its research and development activities are dedicated to software, and a large part of these research are on AI.

According to John McCarthy, a professor at the Computer Science Department of Stanford University, AI is defined as “the science and engineering of making intelligent machines, especially intelligent computer programs. It is related to the similar task of using computers to understand human intelligence, but AI does not have to confine itself to methods that are biologically observable”.

The development and usage of energy-based aesthetic devices for medical and cosmetic procedures has increased exponentially over the past years. The report covers the aesthetic lasers and energy devices used for the rejuvenation of hair and skin. However, the report does not include services for these devices. The aesthetic lasers and energy devices market is segmented on the basis of technology, product, application, end users, and region.

The global advanced dermatology drug delivery devices market is driven by factors such as the global efforts in increasing the adoption of connected devices, increasing number of business synergies with pharmaceutical companies, novel technologies in drug delivery, and the growing focus on prescription/medication adherence. Manufacturers are more focused on producing devices that offer enhanced patient experience through real-time monitoring and data sharing. The succeeding figure indicates the impact analysis for the different market growth promoting and restraining factors during the forecast period 2021-2030.

Amid the tragic consequences of COVID-19, life sciences and medtech companies emerged as lights in the darkness. Decades of scientific work and investment seemed to be overnight successes. The heroic dedication of health care providers was met by the fastest novel vaccine development in history. Traditional competitors partnered to accelerate research and manufacturing. When one company failed, it joined the other to accelerate the development and manufacture of a successful vaccine. Governments, retail pharmacies, health systems, payers, and nonprofits are working together to provide widespread distribution and administration.

The landscape of hematological malignancies emerging therapeutics is massively growing, with many emerging and legacy companies venturing into the industry with their respective therapeutic portfolio exclusively developed and designed for the targeted treatment of hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In the era of precision medicine, the introduction of monoclonal antibody- and CAR-T cell-based therapies have garnered a new hope in the oncology community, owing to their ability to induce effective response for the treatment of hematological malignancies. Hematological malignancies are very complex to treat due to their varying pathological and immunological characteristics, which makes it evident to use a more precise and targeted approach for its clinical management. The current scenario of the clinical development of emerging therapeutics in the hematological malignancy ecosystem is well sprung, as so many pharmaceutical giants and small-scale biotechnology companies are lined up to get their therapies in the market.

Virtual reality technology is widely applied in rehabilitation therapy and is termed virtual rehabilitation. VR is a computer-based intervention providing patients with a virtual interactive and applicable treatment setting for skills practice with real-time feedback. Virtual rehabilitation can be used both at home. Most virtual rehabilitation systems developed require motor training which includes complex and expensive hardware and can be used only under professional guidance, such as in hospitals, rehab centers, and clinical settings. Many low-cost rehabilitation gaming systems have been developed for patients with movement disorders. These systems are for home use and require remote supervision of a therapist. The home-use virtual rehabilitation systems promote physical rehabilitation at home and reduce frequent hospital visits, which have reduced healthcare costs.